Andere Sprachen Cardiol Therapeutics Inc.

Aktien

A2PA9E

CA14161Y2006

CRDL

Markt geschlossen - Toronto S.E. Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
2,84 ^CAD	+2,16 %		+18,33 %	+158,18 %

23.04.	CARDIOL THERAPEUTICS INC. : HC Wainwright behält die Bewertung Kaufen bei	ZM
01.04.	Cardiol Therapeutics Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cardiol Therapeutics : Notice of Meeting and Record Date - Form 6-K	26.04.
Cardiol Therapeutics Announces Year-End 2023 Update on Operations	02.04.
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis	21.02.
Cardiol Therapeutics Inc. Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx? for Recurrent Pericarditis	21.02.
Cardiol Therapeutics Receives Orphan Drug Designation From FDA for Lead Drug Candidate to Treat Pericarditis	15.02.
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis	15.02.
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market	24.01.
Cardiol Therapeutics Enrolls Over 50% of Patients for Phase II ARCHER Trial in Acute Myocarditis	09.01.
Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis	09.01.
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis	09.01.
Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot	06.12.
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot	05.12.
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases	16.11.
CARDIOL THERAPEUTICS : CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 - Form 6-K	15.11.
Cardiol Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis	01.11.
Cardiol Therapeutics Inc. Announces 50% Enrollment in Its Phase Ii Maveric-Pilot Study in Recurrent Pericarditis	01.11.
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	23.10.23
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	20.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cardiol Therapeutics Inc.

Aktien

A2PA9E

CA14161Y2006

CRDL

Andere Sprachen

Filter